Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report

Current Oncology

卷:28

Lucy Gilbert¹  Thierry Alcindor²  Sungmi Jung³ 

[1] Cedars Cancer Center, Division of Gynecologic Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada;

[2] Cedars Cancer Center, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada;

[3] Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada;

关键词: adenosarcoma;    sarcoma;    immunotherapy;    targeted therapy;   

DOI  :  10.3390/curroncol28030199

来源: DOAJ

【 摘 要 】

A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.

【 授权许可】

Unknown